Anne Erickson biography
Anne Erickson is the IR Contact Officer at Savara Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Anne Erickson's mailing address?
Anne's mailing address filed with the SEC is 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Insiders trading at Savara Inc
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer